HARROW, INC.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
HROW$30.36+10.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
CONSOLIDATED BALANCE SHEETS
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $47,247,000 | $74,085,000 |
| Investment in Eton Pharmaceuticals | - | 8,681,000 |
| Accounts receivable, net | 116,373,000 | 36,261,000 |
| Inventories | 10,702,000 | 10,867,000 |
| Prepaid expenses and other current assets | 15,329,000 | 9,588,000 |
| Total current assets | 189,651,000 | 139,482,000 |
| Property, plant and equipment, net | 3,734,000 | 3,521,000 |
| Capitalized software costs, net | 1,751,000 | 2,138,000 |
| Operating lease right-of-use assets, net | 8,554,000 | 6,785,000 |
| Intangible assets, net | 184,949,000 | 159,906,000 |
| Goodwill | 332,000 | 332,000 |
| TOTAL ASSETS | $388,971,000 | $312,164,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $41,406,000 | $24,581,000 |
| Accrued rebates and copay assistance | 39,900,000 | 18,432,000 |
| Accrued payroll and related liabilities | 9,496,000 | 5,450,000 |
| Deferred revenue and customer deposits | 44,000 | 75,000 |
| Current portion of operating lease obligations | 497,000 | 806,000 |
| Total current liabilities | 91,343,000 | 49,344,000 |
| Operating lease obligations, net of current portion | 8,792,000 | 6,524,000 |
| Notes payable, net of unamortized debt discounts | 219,539,000 | 185,885,000 |
| TOTAL LIABILITIES | 319,674,000 | 241,753,000 |
| Commitments and contingencies | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Common stock, $0.001 par value, 50,000,000 shares authorized, 35,622,214 and 35,168,260 shares issued and outstanding at December 31, 2024 and 2023, respectively | 35,000 | 35,000 |
| Additional paid-in capital | 221,002,000 | 204,635,000 |
| Accumulated deficit | (151,385,000) | (133,904,000) |
| TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY | 69,652,000 | 70,766,000 |
| Noncontrolling interests | (355,000) | (355,000) |
| TOTAL STOCKHOLDERS’ EQUITY | 69,297,000 | 70,411,000 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $388,971,000 | $312,164,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.